China Immuno-Oncology Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Immuno-Oncology Market was valued at USD 1.90 billion in 2025 and is projected to reach USD 2.82 billion by 2032, growing at a CAGR of approximately 5.8% during 2026–2032.
China Immuno-Oncology Market Highlights
| Report Metric | Details |
| Report Name | China Immuno-Oncology Market |
| Market Size 2025 | USD 1.90 billion |
| Market Size 2032 | USD 2.82 billion |
| Absolute Growth 2025–2032 | USD 0.92 billion |
| CAGR 2026–2032 | 5.8% |
| Peak Annual Growth | 8.1% in 2030 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapy Type, 2025 | Checkpoint Inhibitors (38% share) |
| Leading Cancer Type, 2025 | Lung (31% share) |
| Leading Mode of Administration, 2025 | IV/Injectable (36% share) |
| Leading End User, 2025 | Oncology Hospitals (48% share) |
| Fastest-Growing Therapy Type | Tumor Vaccines (8.5% CAGR) |
| Fastest-Growing Cancer Type | Pancreatic (7.1% CAGR) |
| Fastest-Growing Mode of Administration | Personalized Infusion (8.1% CAGR) |
| Fastest-Growing End User | Immunotherapy Clinics (7.9% CAGR) |
| Growing Sector | Oncology Hospitals |
| Key End Users | Oncology Hospitals, Immunotherapy Clinics, Research Institutions |
China Immuno-Oncology Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The following table presents the estimated annual growth rate for each year together with the principal factor influencing market performance.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 7.2 | The market experienced strong growth due to increased demand for advanced cancer therapies. |
| 2023 | 6.4 | Growth slowed as the market adjusted to new treatment protocols and regulatory changes. |
| 2024 | 5.6 | Demand continued to rise, albeit at a slower pace, as new therapies entered the market. |
| 2025 | 6.9 | Growth accelerated again due to expanding oncology hospital networks and treatment options. |
| 2026 | 4.4 | Market growth is expected to slow as the focus shifts towards improving existing therapies. |
| 2027 | 6.8 | Demand will increase with the introduction of more CAR-T cell therapy centres across the country. |
| 2028 | 7.8 | Growth is projected to pick up as patient visits to immunotherapy clinics surge significantly. |
| 2029 | 3.7 | A slowdown is anticipated as the market faces challenges in regulatory approvals for new treatments. |
| 2030 | 8.1 | The market is expected to peak with a surge in demand for checkpoint inhibitors and CAR-T therapies. |
| 2031 | 6.7 | Growth will slow as the market matures and competition intensifies among treatment providers. |
| 2032 | 3.2 | The market is projected to grow at a slower rate as it stabilises after rapid expansion. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Immuno-Oncology Market Synopsis
Immuno-Oncology in China encompasses therapies that harness the immune system to combat cancer. This includes advanced treatments like checkpoint inhibitors and CAR-T cell therapy, developed through sophisticated biotechnological processes. The China Immuno-Oncology Market is experiencing growth driven by a high prevalence of cancer cases, with approximately 4.5 million patients reported in 2023. The expansion is supported by increasing investments in healthcare infrastructure and ongoing clinical trials, leading to greater availability of therapies that improve patient outcomes.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Growing prevalence of lung cancer necessitates advanced treatment options. | Driver | High | Checkpoint Inhibitors |
| Rising patient visits to immunotherapy clinics boosts demand for therapies. | Driver | High | CAR-T Cell Therapy |
| Increased funding for cancer research creates opportunities for new therapies. | Opportunity | High | Tumor Vaccines |
| Expansion of specialized oncology hospitals opens new markets for immuno-oncology. | Opportunity | High | Oncology Hospitals |
| High treatment costs limit access for a significant portion of the population. | Restraint | High | CAR-T Cell Therapy |
| Regulatory hurdles delay the approval of new immuno-oncology drugs. | Restraint | Medium | Checkpoint Inhibitors |
| Limited awareness among patients about available immuno-oncology treatments. | Challenge | Medium | Tumor Vaccines |
| Competition among treatment providers may lead to pricing pressures. | Challenge | Medium | Oncology Hospitals |
Evaluation of Drivers in China Immuno-Oncology Market (2026–2032)
Below mentioned are some major drivers and their influence on market dynamics.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased investment in cancer research and development. | Checkpoint Inhibitors | The National Key Research and Development Program allocated 1 billion CNY for cancer research funding, improving treatment options. |
| Growing patient population seeking advanced therapies. | CAR-T Cell Therapy | With 4.5 million cancer patients in China, demand for effective treatments continues to rise, driving market growth. |
| Rising number of oncology hospitals providing specialized care. | Oncology Hospitals | Over 4,000 oncology hospitals are expanding their services to include immuno-oncology treatments, increasing access for patients. |
| Improved regulatory pathways for drug approvals. | Checkpoint Inhibitors | The Chinese FDA updated approval processes, allowing faster access to new therapies, facilitating quicker patient treatment. |
| Increasing awareness of immuno-oncology benefits among healthcare providers. | Tumor Vaccines | Educational initiatives by the China Cancer Society have improved understanding of immunotherapy, leading to higher adoption rates. |
Expansion of the Immuno-Oncology market in China is backed by increased investment in cancer research and development, alongside a growing patient population. The National Health Commission's 'Cancer Prevention and Control Plan' allocated 1 billion CNY for cancer research funding, which improves treatment options. Approximately 4.5 million cancer patients in China are driving demand for effective therapies. The rise in oncology hospitals, now exceeding 4,000, is expanding access to immuno-oncology treatments. Updated approval processes from the Chinese FDA allow quicker access to new therapies, stimulating further demand.
Evaluation of Restraints in China Immuno-Oncology Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| High costs of CAR-T therapies limit patient access. | CAR-T Cell Therapy | The average treatment cost for CAR-T therapy is approximately 500,000 CNY, restricting affordability. |
| Regulatory hurdles delay new drug approvals. | Checkpoint Inhibitors | The lengthy approval process can hinder timely access to new therapies, with delays lasting several months. |
| Limited patient awareness of immuno-oncology options. | Tumor Vaccines | Many patients remain unaware of the benefits and availability of immuno-oncology treatments, affecting uptake. |
| Competition among providers may lead to pricing pressures. | Oncology Hospitals | Intense competition can force hospitals to lower prices, impacting profitability and investment in new treatments. |
| Insufficient infrastructure in rural areas for treatment delivery. | CAR-T Cell Therapy | Patients in rural regions face challenges accessing specialized cancer treatments, limiting their options. |
China Immuno-Oncology Market Challenges
The China immuno-oncology market still has to solve a few problems, and the first is intense competition among over 4,000 oncology hospitals, which drives down prices and reduces profit margins for suppliers. Regulatory challenges create delays in the approval of new treatments, costing producers valuable time and resources, which can hinder patient access to essential therapies. Buyers are burdened with rising treatment costs, especially for CAR-T therapy, averaging 500,000 CNY, complicating budget management for healthcare providers. A shortage of skilled professionals in advanced immunotherapy techniques restricts clinics' capabilities, affecting the quality of care for 4.5 million cancer patients nationwide.
Trends in the China Immuno-Oncology Market
Four trends stand out in the China Immuno-Oncology Market.
- Shift from Traditional to Immuno-Oncology Treatments: Since 2022, urban oncology hospitals have increasingly adopted immuno-oncology therapies. This change is evidenced by checkpoint inhibitors being used in 60% of lung cancer therapies in urban areas.
- Increase in CAR-T Cell Therapy Centres: In 2023, over 100 specialized centres for CAR-T cell therapy were established across China. This expansion reflects a growing recognition of the therapy's effectiveness in treating hematological malignancies.
- Rising Demand for Tumor Vaccines: The demand for tumor vaccines increased by 25% in the last year, driven by ongoing clinical trials and research initiatives led by the China Cancer Society.
- Surge in Patient Visits to Immunotherapy Clinics: Immunotherapy clinics have seen a 30% increase in patient visits annually, indicating a growing acceptance of these advanced treatment options among cancer patients.
Investment Opportunities in the China Immuno-Oncology Market
Below are the investment opportunities with the strongest case in the China Immuno-Oncology Market.
- Oncology Hospitals Seeking Advanced Therapies: Oncology hospitals are increasingly looking for advanced immuno-oncology treatments to improve their offerings. With rising patient numbers, the demand for new therapies is significant, particularly for those that enhance treatment outcomes.
- Investment in CAR-T Cell Therapy Infrastructure: The establishment of CAR-T cell therapy centres presents a lucrative opportunity for investment. With over 100 centres already operational, there is potential for further expansion to meet growing demand.
- Growing Market for Tumor Vaccines: The rising demand for tumor vaccines, which increased by 25% last year, highlights a gap in the market. Targeting research institutions can facilitate entry into this segment, providing innovative solutions.
- Timing for Personalized Infusion Therapies: With personalized infusion therapies being adopted in over 200 hospitals nationwide, the current focus on tailored treatments presents a timely opportunity for suppliers to meet specific patient needs.
Government Initiatives in the China Immuno-Oncology Market
The 'Cancer Prevention and Control Plan' launched by the National Health Commission in 2021 aims to reduce cancer mortality by 10% by 2030. This initiative encourages hospitals to adopt advanced therapies, improving patient outcomes. Additionally, the State Council introduced the 'Healthy China 2030' initiative in 2020, which emphasizes improvements in cancer prevention and treatment. This framework supports funding and resources for cancer-related research and therapies, benefiting producers and healthcare providers alike. In 2022, the National Medical Products Administration updated approval pathways for immuno-oncology drugs to expedite patient access to these advanced treatments.
In 2023, the Chinese FDA established a new regulatory framework for CAR-T cell therapies to improve safety and efficacy standards. This measure aims to expedite patient access to these advanced treatments. The Ministry of Science and Technology continues to support cancer research initiatives through the 'National Key Research and Development Program', providing funding and resources for new therapies. These agencies play a crucial role in ensuring that new treatments are both effective and accessible to patients, with the program allocating significant resources to support ongoing research.
Future Insight of the China Immuno-Oncology Market
The China immuno-oncology market is expected to develop by 2032, driven by advancements in genetic engineering and the launch of more specialized treatment centers. The 'Cancer Prevention and Control Plan' will allocate 1 billion CNY for cancer research funding, facilitating the introduction of new therapies. An increase in patient visits to immunotherapy clinics by 30% annually reflects a growing acceptance of these treatments. The expansion of clinical trials, with over 30 currently ongoing, will likely provide additional options for both buyers and suppliers.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Therapy Type – Checkpoint Inhibitors Dominated, Tumor Vaccines Expected to Grow Fastest
According to Sachin Kumar Rai, Senior Research Analyst at 6Wresearch, Checkpoint Inhibitors took a 38% share of therapy type in 2025, more than any other category. Checkpoint inhibitors dominate the market as they are the primary treatment for various cancers, especially lung cancer, which has a high prevalence in urban areas. Their integration into 60% of lung cancer therapies in cities underscores their critical role in cancer care. Tumor Vaccines are set to record the highest CAGR in this split, 8.5% over 2026–2032. The demand for tumor vaccines is rapidly increasing, driven by a 25% rise in interest over the past year, reflecting the growing focus on preventive strategies in cancer treatment. This trend is supported by numerous ongoing clinical trials aiming to validate their effectiveness. Suppliers must prioritise the development of tumor vaccines to align with the increasing demand and shifting treatment paradigms.
By Cancer Type – Lung Dominated, Pancreatic Expected to Grow Fastest
Lung held a 31% share of the China Immuno-Oncology Market by cancer type in 2025. Lung cancer dominates the market as it is the most prevalent cancer type in China, contributing to 20% of all cancer-related deaths. The substantial patient population, estimated at 4.5 million, creates a robust demand for effective immuno-oncology treatments. The quickest growth will come from Pancreatic, forecast to expand at a CAGR of 7.1% between 2026 and 2032. Pancreatic cancer is witnessing the highest growth rate, propelled by intensified research initiatives and funding aimed at enhancing treatment methodologies. This surge underscores a growing awareness of the need for effective therapies for less common cancers. Suppliers should consider increasing their focus on pancreatic cancer research to align with the rising demand for targeted treatment options.
By Mode of Administration – IV/Injectable Dominated, Personalized Infusion Expected to Grow Fastest
The largest mode of administration category in 2025 was IV/Injectable, with a 36% share of total revenue. IV/Injectable therapies hold the largest market share as they are the most common mode of administration for cancer treatments. Their established use in oncology hospitals ensures a steady demand among healthcare providers. Personalized Infusion is projected to grow fastest, at a CAGR of 8.1% during 2026–2032. Personalized infusion therapies are gaining traction, reflecting a shift towards tailored treatment approaches that cater to individual patient needs. This method's adoption in over 200 hospitals indicates a growing preference for customised care in oncology. Suppliers should consider expanding their portfolios to include personalized infusion options to meet the evolving preferences of healthcare providers.
By End User – Oncology Hospitals Dominated, Immunotherapy Clinics Expected to Grow Fastest
Oncology Hospitals accounted for a 48% market share by end user in 2025. Oncology hospitals hold the largest market share as they are the primary facilities providing cancer treatment across China. Their established infrastructure and comprehensive care capabilities make them vital players in the immuno-oncology sector. Over 2026–2032, Immunotherapy Clinics are expected to post the fastest growth, at a CAGR of 7.9%. Immunotherapy clinics are rapidly expanding, with a notable 30% annual increase in patient visits, indicating a shift towards specialised immuno-oncology care. This trend highlights the growing importance of dedicated treatment centres in the market. Suppliers should seek collaborations with immunotherapy clinics to leverage this growth and strengthen their market position.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Immuno-Oncology Market Outlook
- Market Size of China Immuno-Oncology Market, 2025
- Forecast of China Immuno-Oncology Market, 2032
- Historical Data and Forecast of China Immuno-Oncology Revenues & Volume for the Period 2022 - 2032F
- China Immuno-Oncology Market Trend Evolution
- China Immuno-Oncology Market Drivers and Challenges
- China Immuno-Oncology Price Trends
- China Immuno-Oncology Porter's Five Forces
- China Immuno-Oncology Industry Life Cycle
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Therapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Checkpoint Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By CAR-T Cell Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Tumor Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Oncolytic Virus Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Cancer Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Lung, Melanoma for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Leukemia, Lymphoma for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Pancreatic, Cervical for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Solid Tumors for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Mode of Administration for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By IV/Injectable for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Personalized Infusion for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Intradermal for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By IV/Intratumoral for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Oncology Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Cellular Therapy Units for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Immunotherapy Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of China Immuno-Oncology Market Revenues & Volume By Experimental Units for the Period 2022 - 2032F
- China Immuno-Oncology Import Export Trade Statistics
- Market Opportunity Assessment By Therapy Type
- Market Opportunity Assessment By Cancer Type
- Market Opportunity Assessment By Mode of Administration
- Market Opportunity Assessment By End User
- China Immuno-Oncology Top Companies Market Share
- China Immuno-Oncology Competitive Benchmarking By Technical and Operational Parameters
- China Immuno-Oncology Company Profiles
- China Immuno-Oncology Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Therapy Type
- Checkpoint Inhibitors
- CAR-T Cell Therapy
- Tumor Vaccines
- Oncolytic Virus Therapy
By Cancer Type
- Lung
- Melanoma
- Leukemia
- Lymphoma
- Pancreatic
- Cervical
- Solid Tumors
By Mode of Administration
- IV/Injectable
- Personalized Infusion
- Intradermal
- IV/Intratumoral
By End User
- Oncology Hospitals
- Cellular Therapy Units
- Immunotherapy Clinics
- Experimental Units
